Sinclair Research announced new scientific leadership with the arrival of Jeffrey Klein, Ph.D., DABT, as director of toxicology and dermatology. In this newly created role, Klein will be responsible for the company’s scientific direction in toxicology and dermatology services and their operational processes. He will drive the growth of Sinclair’s business model and foster positive relationships with new and current customers.
Klein joins Sinclair Research from EP Technologies in Akron, Ohio, where he directed preclinical research including discovery, toxicology and management of active transdermal technology. He held a similar position at Noven Pharmaceuticals working with passive transdermal technology. His preclinical knowledge and experience from the pharmaceutical and contract research organization industries will be of significant value to Sinclair and all its customers.
“Jeff is an exciting new addition to the Sinclair research staff. In addition to his extensive experience in general toxicology and program management, he significantly enhances our scientific depth in the area of dermatology. Jeff will be an invaluable resource for clients developing products in this area,” said G. Alex Wakefield, Sinclair’s vice president of research and operations.